40167-37-1

Upstream product

• 1885-38-7 cinnamic nitrile 
• 87022-42-2 1-(isocyanomethyl)-1H-benzo[d][1,2,3]triazole 
• 36635-63-9 ((isocyanomethyl)sulfonyl)benzene 
• 14378-06-4 (E)-α-cyanocinnamic acid 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 104919-31-5 3-oxo-2-[1-phenylmeth-(E)-ylidene]butyronitrile 
• 71333-60-3 (E)-1-Isocyano-2-phenyl-1-tosylethene 
• 105-56-6 ethyl 2-cyanoacetate 
• 4360-47-8 cinnamonitrile 

Downstream Products

• 934290-40-1 C₁₉H₁₄N₂O₂ 
• 1072198-74-3 2-(3-Cyano-4-phenylpyrrole-1-yl)isonicotinic acid ethyl ester 
• 1072198-76-5 5-(3-Cyano-4-phenylpyrrole-1-yl)-2-methoxymethoxy-benzoic acid ethyl ester 
• 1072202-85-7 5-benzyloxy-2-(3-cyano-4-phenylpyrrole-1-yl)isonicotinic acid ethyl ester 
• 934290-41-2 4-(3-cyano-4-phenylpyrrole-1-yl)benzoic acid 
• 348637-56-9 1-methyl-4-phenyl-1H-pyrrole-3-carbonitrile 
• 1352087-37-6 N-tert-butyl-8-cyano-6-fluoro-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide 
• 1352087-36-5 6-fluoro-7-phenyl-1,2,3,4-tetrahydropyrrolo-[1, 2-a]pyrazine-8-carbonitrile 
• 1352087-35-4 tert-butyl {2-[4-cyano-2-fluoro-3-phenyl-1H-pyrrol-1-yl]ethyl}carbamate 
• 1352087-34-3 5-fluoro-4-phenyl-1H-pyrrole-3-carbonitrile 
• 1352086-69-1 N²-tert-butyl-6-fluoro-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide 
• 1352087-23-0 N-tert-butyl-6-chloro-8-cyano-7-phenyl-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide 
• 1352087-22-9 6-chloro-7-phenyl-1,2,3,4-tetrahydropyrrolo-[1, 2-a]pyrazine-8-carbonitrile 
• 1352087-21-8 tert-butyl {2-[2-chloro-4-cyano-3-phenyl-1H-pyrrol-1-yl]ethyl}carbamate 

Relevant academic research and scientific papers

Mechanochemical Syntheses of N-Containing Heterocycles with TosMIC

A mechanochemical van Leusen pyrrole synthesis with a base leads to 3,4-disubstitued pyrroles in moderate to excellent yields. The developed protocol is compatible with a range of electron-withdrawing groups and can also be applied to the synthesis of oxazoles. Attempts to mechanochemically convert the resulting pyrroles into porphyrins proved to be difficult.

Solvent-Controlled C2/C5-Regiodivergent Alkenylation of Pyrroles

A solvent-controlled C2/C5-selective alkenylation of 3,4-disubstituted pyrroles has been developed. The C3 substituent of pyrroles proved crucial to the regioselectivity. Substrates bearing directing groups at the C3 position exhibited excellent C2-select

SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS

The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

Tandem Michael addition/isocyanide insertion into the C-C bond: A novel access to 2-acylpyrroles and medium-ring fused pyrroles

A new reaction model, tandem Michael addition/formal isocyanide insertion into the acyl C-C bond, has been developed. Thus, a series of 2-acylpyrroles and seven-/eight-membered ring fused pyrroles were synthesized from the reaction of methyl isocyanides with enones in a single operation.

3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

Compounds corresponding to the general formula (I) wherein R2 represents a group C1-10-alkyl, C3-10-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyl-C3-7-cycloalkyl, C3-7

3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

Compounds corresponding to the general formula (I) in which R2 represents a group C1-10-alkyl, C3-10- cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyl- C3-7-cycloalkyl, C

NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4) ; Y2 represents N or C(R5) ; R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxygroup or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, ahalogenatometc.; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

Syntheses of imidazoles and pyrroles: Betmic and tosmic as complementary reagents

p-Tolylsulfonylmethyl isocyanide (TosMIC) and benzotriazol-1-yl-methyl isocyanide (BetMIC) were compared as to their synthetic utilities for the synthesis of imidazoles and pyrroles and found to be complementary.

Synthesis of 3,4-Disubstituted Pyrroles Bearing Substituents of Electron-Withdrawing and/or Electron-Donating Nature

The synthesis is described of a series of 3,4-disubstituted pyrroles 8 from 1-isocyano-1-tosyl-1-alkenes and a variety of Michael donors.It is possible to use this method for the synthesis of pyrroles that bear no electron-withdrawing substituents.